文献速递肺外科

国家肺癌筛查试验与当代实践中的手术结局比较

Surgical Outcomes in the National Lung Screening Trial Compared With Contemporary Practice.
PubMed 文献 · Ann Thorac Surg · 2022-01-07

本研究比较国家肺癌筛查试验(NLST)与2014至2015年国家癌症数据库(NCDB)中非小细胞肺癌肺切除患者的围手术期结局。经风险与可靠性调整后,NCDB医院平均30天和90天死亡率均显著高于NLST医院,且NCDB医院间死亡率变异明显,而NLST医院间调整后死亡率相似。

要点

  • NCDB医院调整后平均30天死亡率2.2%显著高于NLST医院1.8%。
  • NCDB医院调整后平均90天死亡率4.2%显著高于NLST医院2.9%。
  • NCDB医院间调整后30天死亡率变异范围为1.1%至4.9%,90天为2.6%至9.7%。

核心结论

  • 与国家肺癌筛查试验中观察到的结局相比,全国队列中经风险与可靠性调整的术后死亡率变异很大。
  • 需要努力减少这种变异,以确保美国充分实现肺癌筛查的益处。

研究设计与样本

  • 识别2014至2015年国家癌症数据库中诊断为非小细胞肺癌并接受肺切除的患者,以及国家肺癌筛查试验中的相应患者。
  • 比较两个数据集的人口学和癌症特征,并使用分层逻辑回归比较各机构间30天和90天术后死亡率。

主要发现

  • 共纳入NCDB患者65054例(来自1119家NCDB医院)和NLST患者1003例(来自33家NLST医院)。
  • 经风险与可靠性调整后,NCDB医院平均30天死亡率2.2%(95%CI 2.2至2.2)显著高于NLST医院1.8%(95%CI 1.8至1.8),P<.001。
  • 经风险与可靠性调整后,NCDB医院平均90天死亡率4.2%(95%CI 4.2至4.3)显著高于NLST医院2.9%(95%CI 2.9至2.9),P<.001。
  • NCDB医院间经风险与可靠性调整的30天死亡率变异范围为95%CI 1.1%至4.9%,90天死亡率变异范围为95%CI 2.6%至9.7%。
  • NLST机构间调整后死亡率相似(30天1.8%至1.8%,90天2.9%至2.9%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The National Lung Screening Trial (NLST) established a role for lung cancer screening. Mortality benefits with screening are predicated on successful treatment with low surgical mortality. Given variations observed in perioperative outcomes after lung cancer resection, it remains unknown whether benefits observed in the NLST are generalizable to a broader population. We sought to determine whether NLST perioperative outcomes are reflective of contemporary practice in a national cohort. METHODS: We identified patients diagnosed with non-small cell lung cancer who underwent lung resection in the 2014 to 2015 National Cancer Database (NCDB) and the NLST. We compared demographic and cancer characteristics in both datasets. We used hierarchical logistic regression to compare 30-day and 90-day postoperative mortality across facilities in both datasets. RESULTS: In all, 65054 patients in NCDB and 1003 patients in the NLST treated across 1119 NCDB hospitals and 33 NLST hospitals were included. After risk and reliability adjustment, mean 30-day and 90-day mortality were significantly higher among NCDB hospitals (mean 30-day, 2.2 [95% confidence interval (CI), 2.2 to 2.2] vs 1.8 [95% CI, 1.8 to 1.8], P < .001; mean 90-day, 4.2 [95% CI, 4.2 to 4.3] vs 2.9 [95% CI, 2.9 to 2.9], P < .001). Variation in risk- and reliability-adjusted 30-day mortality (95% CI, 1.1% to 4.9%) and 90-day mortality (95% CI, 2.6% to 9.7%) was observed among NCDB hospitals. Adjusted mortality was similar among NLST facilities (30 days, 1.8% to 1.8%; 90 days, 2.9% to 2.9%). CONCLUSIONS: Risk- and reliability-adjusted postoperative mortality varies widely in a national cohort compared with outcomes observed in the NLST. Efforts to minimize this variation are needed to ensure that benefits of lung cancer screening are fully realized in the United States.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Savitch SL, Zheng R, Abdelsattar ZM, et al. Surgical Outcomes in the National Lung Screening Trial Compared With Contemporary Practice. Ann Thorac Surg. 2022. PMID: 35007506. doi:10.1016/j.athoracsur.2021.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。